CTIC : Summary for CTI BioPharma Corp. - Yahoo Finance

U.S. Markets closed

CTI BioPharma Corp. (CTIC)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.17-0.28 (-5.14%)
At close: 4:00PM EST

5.30 0.13 (2.61%)
After hours: 5:18PM EST

People also watch
AGENHEBXOMAKERXGERN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.45
Open5.35
Bid4.50 x 500
Ask5.62 x 300
Day's Range4.85 - 5.35
52 Week Range0.25 - 6.48
Volume390,438
Avg. Volume856,650
Market Cap145.93M
Beta-0.03
PE Ratio (TTM)-18.46
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Accesswire9 days ago

    Latest Reports on Recent Market Movers: 3D Systems and CTI BioPharma

    NEW YORK, NY / ACCESSWIRE / January 10, 2017 / The Dow Jones Industrial Average pulled back Monday after nearly breaking the 20,000 point plateau Friday. Declines by financial and energy sectors pressured ...

  • PR Newswire10 days ago

    CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017

    SEATTLE, Jan. 9, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced positive progress on its lead programs in addition to key business priorities for 2017. "Throughout 2016 we maintained our commitment to bringing new therapies to patients with unmet medical needs, and were successful in working with the FDA to remove the full clinical hold on pacritinib and get it back on the development track for the benefit of myelofibrosis patients," said Richard Love, Interim President and Chief Executive Officer of CTI BioPharma. "The PERSIST-2 clinical trial of pacritinib was highlighted as one of six late-breaking data presentations at the American Society of Hematology conference in December.  We believe this oral presentation was well received by the hematology/oncology community, which recognizes the unmet need for myelofibrosis patients who are  ineligible to receive or are not benefitting from the approved JAK1/JAK2 inhibitor, ruxolitinib.

  • American City Business Journals12 days ago

    CTI Biopharma stock revived after FDA ruling, reverse stock split

    CTI BioPharma Corp.’s stock is up ten-fold this week after the Food and Drug Administration lifted a year-long clinical suspension and the company executed a reverse stock split. CTI’s share price has increased about 22 percent since Thursday, when it was announced that the FDA lifted a hold on myelofibrosis drug trials using the Seattle-based biotech company’s lead pipeline drug pacritinib. CTI's board of directors in December approved the split to raise stock price to $1 per share for a minimum of 10 consecutive trading days by March 20, 2017, in line with Nasdaq exchange minimum requirements.